journal article·2025-07-15

An Asynchronous-Regulated Nanosheet Cascade Amplifies Sonodynamic-Triggered Self-Enhanced DNA Damage for Intensive Tumor Immunotherapy

Rui Luo, Xinchao Li, Miaomiao Zhang, Dongxue Huang, Hao Le, Tao He, Xiye Wang, Xiaorong Kou, Xinyue Wu, Qinjie Wu, Changyang Gong

ACS Nano· Volume 19· Issue 27
Publisher page

Abstract

DNA damage can potentially trigger innate immune responses, providing a feasible way for immunotherapies to target “cold” tumors (T cell-deprived). However, DNA damage resistance and immunosuppression severely compromise tumor therapeutic efficacy. We therefore developed an ultrasound-activat e d and asyn ch ronous-regulated nan o sheet (ECHO). This system achieved cascade amplification of self-enhanced DNA damage via sonodynamic therapy, enabling potent tumor immunotherapy. Upon ultrasound activation, the peroxidase-like property conferred ECHO with the capability to induce precise and potent DNA damage by triggering ROS explosions, while leveraging the Russell mechanism to continuously generate ROS within the tumor microenvironment, heightening cellular susceptibility to DNA damage. Then, STING was activated and enhanced by DNA fragments and Mn 2+ released from ECHO, respectively, which in turn disrupted ROS clearance for reversing tumor resistance to DNA damage and boosting innate immunity. Simultaneously, Niclosamide inhibited STAT3 in DNA repair response and counteracted immunosuppressive effects. The asynchronous regulation of STING and STAT3 increased ROS absolute content and restrained DNA repairing, facilitating self-enhanced DNA damage, thus intensifying tumor immunotherapy. ECHO effectively targeted tumors with minimal adverse effects, leading to 87% tumor regression and 40% contralateral bilateral tumor elimination. Overall, our asynchronous regulation strategy achieved self-enhancing DNA damage and offered a promising prototype for intensive tumor immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital

Sichuan University

Funding

West China Hospital, Sichuan University · National Key Research and Development Program of China · National Natural Science Foundation of China

References (46)

Show source-provided references
1. 10.1016/j.immuni.2015.01.01210.1016/j.immuni.2015.01.012 ↗
2. 10.1038/nature2344910.1038/nature23449 ↗
3. 10.1002/adma.20230876210.1002/adma.202308762 ↗
4. 10.1016/j.biomaterials.2023.12244410.1016/j.biomaterials.2023.122444 ↗
5. 10.1038/s41392-022-01224-310.1038/s41392-022-01224-3 ↗
6. 10.1038/ni.249110.1038/ni.2491 ↗
7. 10.1172/JCI8689210.1172/JCI86892 ↗
8. 10.1038/ni.355810.1038/ni.3558 ↗
9. 10.1038/s41590-020-0699-010.1038/s41590-020-0699-0 ↗
10. 10.1016/j.immuni.2014.10.01910.1016/j.immuni.2014.10.019 ↗
11. 10.1038/s41467-021-22572-810.1038/s41467-021-22572-8 ↗
12. 10.7150/thno.5817310.7150/thno.58173 ↗
13. 10.1021/jacs.2c0326610.1021/jacs.2c03266 ↗
14. 10.1002/adma.20210683810.1002/adma.202106838 ↗
15. 10.1038/s41467-023-42509-710.1038/s41467-023-42509-7 ↗
16. 10.1002/anie.20231721810.1002/anie.202317218 ↗
17. 10.1016/j.chempr.2020.02.02010.1016/j.chempr.2020.02.020 ↗
18. 10.1002/advs.20230387210.1002/advs.202303872 ↗
19. 10.1016/j.cej.2024.14856110.1016/j.cej.2024.148561 ↗
20. 10.1038/nrc234210.1038/nrc2342 ↗
21. 10.1038/nrc389110.1038/nrc3891 ↗
22. 10.1016/j.ccell.2016.05.01810.1016/j.ccell.2016.05.018 ↗
23. 10.1016/j.coi.2014.01.00410.1016/j.coi.2014.01.004 ↗
24. 10.1016/j.cell.2017.12.02610.1016/j.cell.2017.12.026 ↗
25. 10.1016/j.stem.2016.12.00110.1016/j.stem.2016.12.001 ↗
26. 10.1038/s41586-022-04847-210.1038/s41586-022-04847-2 ↗
27. 10.1038/nature2543210.1038/nature25432 ↗
28. 10.1038/s12276-020-0416-y10.1038/s12276-020-0416-y ↗
29. 10.1038/nrclinonc.2018.810.1038/nrclinonc.2018.8 ↗
30. 10.1016/j.bioactmat.2024.01.02610.1016/j.bioactmat.2024.01.026 ↗
31. 10.1016/j.apsb.2022.09.01710.1016/j.apsb.2022.09.017 ↗
32. 10.1073/pnas.140068311110.1073/pnas.1400683111 ↗
33. 10.1016/j.pharmthera.2022.10811810.1016/j.pharmthera.2022.108118 ↗
34. 10.1016/j.apsb.2023.10.00310.1016/j.apsb.2023.10.003 ↗
35. 10.1038/s41590-021-01047-410.1038/s41590-021-01047-4 ↗
36. 10.1016/j.immuni.2016.01.01410.1016/j.immuni.2016.01.014 ↗
37. 10.1038/s41423-023-01047-410.1038/s41423-023-01047-4 ↗
38. 10.1172/JCI6008310.1172/JCI60083 ↗
39. 10.1002/advs.20180201210.1002/advs.201802012 ↗
40. 10.1093/neuonc/noab196.64710.1093/neuonc/noab196.647 ↗
41. 10.1016/S1074-7613(03)00332-710.1016/S1074-7613(03)00332-7 ↗
42. 10.1002/smtd.20230001910.1002/smtd.202300019 ↗
43. 10.1182/blood.V118.21.185.18510.1182/blood.V118.21.185.185 ↗
44. 10.1038/s41467-023-36550-910.1038/s41467-023-36550-9 ↗
45. 10.1038/s41551-020-00641-510.1038/s41551-020-00641-5 ↗
46. 10.1021/jacs.9b0874410.1021/jacs.9b08744 ↗